Pembrolizumab with lenvatinib and chemotherapy for the treatment of metastatic squamous cell oesophageal carcinoma

Lenvatinib in combination with pembrolizumab and chemotherapy is in clinical development as a first line therapy for metastatic squamous cell oesophageal carcinoma (SCOC). SCOC is a type of cancer that originates in the squamous cells that line the oesophagus (sometimes referred to as the food pipe or gullet). Metastatic cancer means the cancer has spread to other parts of the body. SCOC can be ultimately fatal and symptoms can include difficulty swallowing or eating, weight loss, and pain in the throat or chest that can be very detrimental to patient’s quality of life.